Login / Signup

Systematic Characterization of Antibody-Drug Conjugate Targets in Central Nervous System Tumors.

Shannon CoyJong Suk LeeSabrina J ChanTerri WooJacquelyn JonesSanda AlexandrescuPatrick Y WenPeter Karl SorgerKeith L LigonSandro Santagata
Published in: Neuro-oncology (2023)
CNS tumors exhibit subtype-specific expression of ADC targets including several FDA-approved for other indications. Clinical trials of ADCs in CNS tumors may therefore be warranted.
Keyphrases
  • clinical trial
  • blood brain barrier
  • poor prognosis
  • magnetic resonance imaging
  • drug delivery
  • cerebrospinal fluid
  • open label
  • long non coding rna
  • phase iii